- Trade Name: Voxzogo (BioMarin)
- Indications: Growth deficiency in pediatric patients with achondroplasia.
- Class: Natriuretic, Polypeptide
- Half-life: 21–28 minutes
- FDA Approval Date: 11/19/2021
- Clinically important, potentially hazardous interactions with:
None known - Pregnancy: No available data on vosoritide use in pregnant women.
Please login to view the rest of this drug profile.
Page last updated 07/23/2026
